An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Von Willebrand Disease (vWD)

This study is conducted in Japan of vonicog alfa (rVWF) used to treat pediatric participants with Von Willebrand Disease (vWD). The main aim of the study is to evaluate adverse drug reaction and effectiveness of vonicog alfa (rVWF). During the study, pediatric participants with vWD will be administered with rVWF under routine normal practice. The investigators will evaluate adverse events due to rVWF for 1 year from the start of drug administration. The study sponsor will not be involved in how the participants are administered but will be recorded what happens during the study.

NCT Number	NCT07404644
Lead Sponsor	Takeda
Conditions	Von Willebrand Disease (vWD)
Enrollment	13 participants
Start Date	2026-02-19
Primary Completion	2031-05-30 (estimated)
Study Completion	2031-05-30 (estimated)
Updated on ClinicalTrials.gov	2026-02-23